ALGEN — genOway SA Income Statement
0.000.00%
- €24.51m
- €26.02m
- €20.05m
- 73
- 63
- 33
- 58
Annual income statement for genOway SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | FAS | — | — | FAS | FAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 9.46 | 11 | 14 | 17.1 | 20 |
Cost of Revenue | |||||
Gross Profit | 8.65 | 11 | 12.8 | 16.2 | 19.2 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 10.2 | 11.5 | 14.1 | 15.7 | 18 |
Operating Profit | -0.729 | -0.533 | -0.069 | 1.4 | 2.07 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.973 | -0.611 | -0.092 | 1.08 | 1.96 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.04 | -0.687 | -0.323 | 0.778 | 1.57 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.04 | -0.687 | -0.323 | 0.778 | 1.57 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.04 | -0.687 | -0.323 | 0.778 | 1.57 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.16 | -0.083 | -0.064 | 0.052 | 0.178 |
Dividends per Share |